Bridge Linking Engineering and Society
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
NSABB June-July 2005 Meeting Agenda
First Meeting of the National Science Advisory Board for Biosecurity June 30 – July 1, 2005 Hyatt Regency Bethesda 7400 Wisconsin Ave. Bethesda, Maryland, 20814 USA Hotel Phone: 301-657-1234 Agenda Webcast: To watch the live webcast of the meeting, click here. The webcast can only be viewed when the meeting is in session at 8:00am-6:00pm on June 30 and at 8:00am-1:30pm on July 1 Eastern Time. You will need RealOne Player to view the webcast. If you do not already have RealOne Player on your computer, download here. Presentation slides: To access the following PowerPoint presentations, click on the presentation titles below. June 30, 2005 Opening Remarks and Swearing in Ceremony Elias Zerhouni, M.D. Director of the National Institutes of Health (NIH) Chair's Remarks and Agenda Overview Dennis L. Kasper, M.D. NSABB Chair Harvard Medical School Introduction of NSABB Members NSABB Structure and Operations Thomas Holohan, M.D. NSABB Executive Director, NIH Office of Biotechnology Activities Break Perspectives on Biosecurity in the Life Sciences NSABB Voting Members Impetus for NSABB: Enhancing Biosecurity on the Life Sciences Rajeev Venkayya, M.D. Special Assistant to the President, Senior Director for Biological and Chemical Defense White House Homeland Security Council Perspectives on Biosecurity in the Life Sciences NSABB Ex Officio Members Lunch Session I- The Development of Criteria for Identifying Dual Use Research and Research Results Introduction: Issues of Relevance to Criteria Development Arturo Casadevall, M.D., Ph.D. Professor of Medicine and of Microbiology & Immunology and Chief of Infectious Diseases Albert Einstein College of Medicine National Research Council Perspective: Experiments of Concern Ron Atlas, Ph.D. -
DUPONT DATA BOOK SCIENCE-BASED SOLUTIONS Dupont Investor Relations Contents 1 Dupont Overview
DUPONT DATA BOOK SCIENCE-BASED SOLUTIONS DuPont Investor Relations Contents 1 DuPont Overview 2 Corporate Financial Data Consolidated Income Statements Greg Friedman Tim Johnson Jennifer Driscoll Consolidated Balance Sheets Vice President Director Director Consolidated Statements of Cash Flows (302) 999-5504 (515) 535-2177 (302) 999-5510 6 DuPont Science & Technology 8 Business Segments Agriculture Electronics & Communications Industrial Biosciences Nutrition & Health Performance Materials Ann Giancristoforo Pat Esham Manager Specialist Safety & Protection (302) 999-5511 (302) 999-5513 20 Corporate Financial Data Segment Information The DuPont Data Book has been prepared to assist financial analysts, portfolio managers and others in Selected Additional Data understanding and evaluating the company. This book presents graphics, tabular and other statistical data about the consolidated company and its business segments. Inside Back Cover Forward-Looking Statements Board of Directors and This Data Book contains forward-looking statements which may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. All DuPont Senior Leadership statements that address expectations or projections about the future, including statements about the company’s strategy for growth, product development, regulatory approval, market position, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. -
| Kentucky Spirit(S) | to MARKET , to MARKET
SUMMER 2012 The Grain Chain | | | Kentucky Spirit(s) T O M ARKE T , T O M ARKE T SUMMER 2012 THE magazine Volume 13 | Number 2 The Ag Magazine is published by the from the dean University of Kentucky College of Agriculture. FAR HORIZONS © 2012 University of Kentucky College of Agriculture Kentucky bourbons and wines, cattle, soybeans, and other foodstuffs have found a niche M. Scott Smith in the huge, developing markets of Asia. South America, too, is beginning to open up as Dean a major importer of American agricultural goods. Nancy M. Cox Associate Dean for Research contentsFEATURES The growth of those international markets, as both Director, Kentucky Agricultural Experiment Station population and incomes rise, is key to the remarkable Jimmy C. Henning Associate Dean for Extension expansion of Kentucky farm sales over the last decade— Director, Kentucky Cooperative Extension Service Kentucky Spirit(s) Larry Grabau about one third of the state’s agricultural production is Associate Dean for Instruction “It will make a rabbit walk right up and spit in exported. Despite losing roughly $1 billion of tobacco ______________ a bull dog’s eye.” —Melville Amasa Scovell, speaking in 1906 of rectified whiskeys. and equine sales during this time, farm gate receipts AGRICULTURAL COMMUNICATIONS 8 have increased by about $2 billion. There are many SERVICES DIRECTOR: positive factors in this success, but soaring grain prices Laura Skillman driven by global demand is the largest. EDITOR: The Grain Chain Many forecasters predict that demand for food and Carol L. Spence agricultural products will grow faster than supplies over DESIGNER: In October, it’s only a tiny seed waiting to be Linda Millercox planted. -
Michael S. Brown, MD
DISTINGUISHED PHYSICIANS AND Michael S. Brown, M.D. Sir Richard Roberts, Ph.D. Winner, 1985 Nobel Prize in Physiology or Medicine Winner, 1993 Nobel Prize in Physiology or Medicine MEDICAL SCIENTISTS MENTORING Winner, 1988 Presidential National Medal of Science A globally prominent biochemist and molecular biologist, DELEGATES HAVE INCLUDED... Dr. Brown received the world’s most prestigious medical Dr. Roberts was awarded the Nobel Prize for his prize for his work describing the regulation of the groundbreaking contribution to discovering RNA splicing. cholesterol metabolism. His work laid the foundation for Dr. Roberts is dedicating his future research to GMO crops the class of drugs now called statins taken daily by more than 20 million and food sources, and demonstrating the effect they have on humanity. — GRANDg MASTERS — people worldwide. Ferid Murad, M.D., Ph.D. Mario Capecchi, Ph.D. Boris D. Lushniak, M.D., M.P.H Winner, 1998 Nobel Prize in Physiology or Medicine Academy Science Director The Surgeon General of the United States (acting, 2013-2014) Winner, 2007 Nobel Prize in Physiology or Medicine A world-renowned pioneer in biochemistry, Dr. Murad’s Winner, 2001 National Medal of Science Rear Admiral Lushniak, M.D., M.P.H., was the United award-winning research demonstrated that nitroglycerin Winner, 2001 Lasker Award States’ leading spokesperson on matters of public health, and related drugs help patients with heart conditions by Winner, 2003 Wolf Prize in Medicine overseeing the operations of the U.S. Public Health Service releasing nitric oxide into the body, thus relaxing smooth Mario Capecchi, Ph.D., a biophysicist, is a Distinguished Commissioned Corps, which consists of approximately muscles by elevating intracellular cyclic GMP, leading to vasodilation and Professor of Human Genetics at the University of Utah School of Medicine. -
Iso 14001:2015
Certificate of Approval This is to certify that the Management System of: E. I. du Pont de Nemours and Company 974 Centre Road, Wilmington, DE, 19805, United States has been approved by LRQA to the following standards: ISO 14001:2015 Chris Koci Issued By: Lloyd's Register Quality Assurance, Inc. This certificate is valid only in association with the certificate schedule bearing the same number on which the locations applicable to this approval are listed. Current Issue Date: 21 January 2018 Original Approvals: Expiry Date: 20 January 2021 ISO 14001 – 21 January 2009 Certificate Identity Number: 10052905 Approval Number(s): ISO 14001 – 0011717 The scope of this approval is applicable to: Manufacture of Science-Based Products for Agriculture, Nutrition, Electronics, Communications, Safety and Protection, Home and Construction, Transportation and Apparel Markets. Lloyd's Register Group Limited, its affiliates and subsidiaries, including Lloyd's Register Quality Assurance Limited (LRQA), and their respective officers, employees or agents are, individually and collectively, referred to in this clause as 'Lloyd's Register'. Lloyd's Register assumes no responsibility and shall not be liable to any person for any loss, damage or expense caused by reliance on the information or advice in this document or howsoever provided, unless that person has signed a contract with the relevant Lloyd's Register entity for the provision of this information or advice and in that case any responsibility or liability is exclusively on the terms and conditions set out in that contract. Issued By: Lloyd's Register Quality Assurance, Inc., 1330 Enclave Parkway, Suite 200, Houston, Texas 77077, United States Page 1 of 15 Certificate Schedule Certificate Identity Number: 10052905 Location Activities Global Headquarters ISO 14001:2015 974 Centre Road, Wilmington, DE, 19805, Headquarters Activities in Support of the Global United States Manufacturing Sites and EMS Oversight. -
A Review of J. Craig Venter's a Life Decoded
A peer-reviewed electronic journal published by the Institute for Ethics and Emerging Technologies ISSN 1541-0099 17(1) – March 2008 A review of J. Craig Venter’s A Life Decoded Randy Mayes, Duke University Journal of Evolution and Technology - Vol. 17 Issue 1 – March 2008 - pgs 71-72 http://jetpress.org/v17/mayes.htm In the early 1980s, a number of researchers suggested sequencing and mapping the human genome to help the science community better understand diseases and evolution. Following the announcement that the human genome had been sequenced, scientists wrote in peer-reviewed journals that we are not as hardwired as was once believed, and that the sequencing of the genome was just the beginning. Today, researchers have a new set of goals. In popular journalism, however, the science was lost in the shuffle. The media focused more on the dynamics of the conflicting philosophies of the private and public projects. This emphasis is also clear in the titles of several books chronicling the Human Genome Project, all appearing prior to the recent release of Craig Venter’s autobiography, A Life Decoded: My Genome: My Life (2007). Readers will find that Robert Cook-Deegan’s The Gene Wars (1995) and The Common Thread by Sir John Sulston and Georgina Ferry (2002), both written by insiders, are biased towards the philosophy of the public project, a commons approach. Sulston is a socialist who grows runner beans and drives a second hand car. By contrast, Venter travels in Lear jets and conducts business from his yacht. Three other books are more objective. -
Additives for Polyolefins: Getting the Most out of Polypropylene
ADDITIVES FOR POLYOLEFINS PLASTICS DESIGN LIBRARY (PDL) PDL HANDBOOK SERIES Series Editor: Sina Ebnesajjad, PhD ([email protected]) President, FluoroConsultants Group, LLC Chadds Ford, PA, USA www.FluoroConsultants.com The PDL Handbook Series is aimed at a wide range of engineers and other professionals working in the plastics indus- try, and related sectors using plastics and adhesives. PDL is a series of data books, reference works, and practical guides covering plastics engineering, applications, proces- sing, and manufacturing, and applied aspects of polymer science, elastomers, and adhesives. Recent titles in the series Biopolymers: Processing and Products, Michael Niaounakis (ISBN: 9780323266987) Biopolymers: Reuse, Recycling, and Disposal, Michael Niaounakis (ISBN: 9781455731459) Carbon Nanotube Reinforced Composites, Marcio Loos (ISBN: 9781455731954) Extrusion, 2e, John Wagner and Eldridge Mount (ISBN: 9781437734812) Fluoroplastics, Volume 1, 2e, Sina Ebnesajjad (ISBN: 9781455731992) Handbook of Biopolymers and Biodegradable Plastics, Sina Ebnesajjad (ISBN: 9781455728343) Handbook of Molded Part Shrinkage and Warpage, Jerry Fischer (ISBN: 9781455725977) Handbook of Polymer Applications in Medicine and Medical Devices, Kayvon Modjarrad and Sina Ebnesajjad (ISBN: 9780323228053) Handbook of Thermoplastic Elastomers, Jiri G. Drobny (ISBN: 9780323221368) Handbook of Thermoset Plastics, 2e, Hanna Dodiuk and Sidney Goodman (ISBN: 9781455731077) High Performance Polymers, 2e, Johannes Karl Fink (ISBN: 9780323312226) Introduction -
Humankind 2.0: the Technologies of the Future 6. Biotech
Humankind 2.0: The Technologies of the Future 6. Biotech Piero Scaruffi, 2017 See http://www.scaruffi.com/singular/human20.html for the full text of this discussion A brief History of Biotech 1953: Discovery of the structure of the DNA 2 A brief History of Biotech 1969: Jon Beckwith isolates a gene 1973: Stanley Cohen and Herbert Boyer create the first recombinant DNA organism 1974: Waclaw Szybalski coins the term "synthetic biology” 1975: Paul Berg organizes the Asilomar conference on recombinant DNA 3 A brief History of Biotech 1976: Genentech is founded 1977: Fred Sanger invents a method for rapid DNA sequencing and publishes the first full DNA genome of a living being Janet Rossant creates a chimera combining two mice species 1980: Genentech’s IPO, first biotech IPO 4 A brief History of Biotech 1982: The first biotech drug, Humulin, is approved for sale (Eli Lilly + Genentech) 1983: Kary Mullis invents the polymerase chain reaction (PCR) for copying genes 1986: Leroy Hood invents a way to automate gene sequencing 1986: Mario Capecchi performs gene editing on a mouse 1990: William French Anderson’s gene therapy 1990: First baby born via PGD (Alan Handyside’s lab) 5 A brief History of Biotech 1994: FlavrSavr Tomato 1994: Maria Jasin’s homing endonucleases for genome editing 1996: Srinivasan Chandrasegaran’s ZFN method for genome editing 1996: Ian Wilmut clones the first mammal, the sheep Dolly 1997: Dennis Lo detects fetal DNA in the mother’s blood 2000: George Davey Smith introduces Mendelian randomization 6 A brief History of Biotech -
On Jim Watson's APOE Status: Genetic Information Is Hard to Hide
European Journal of Human Genetics (2009) 17, 147–150 & 2009 Macmillan Publishers Limited All rights reserved 1018-4813/09 $32.00 www.nature.com/ejhg LETTERS 15.6 (95% CI, 10.9–22.5) and 4.3 (95% CI, 3.3–5.5) for APOE e4 homozygotes and e4/e3 heterozygotes respectively, 6 On Jim Watson’s APOE compared to e3 homozygotes. The meta-analytic odds ratios in population-based Caucasian samples were 11.8 status: genetic (95% CI, 7.0–19.8) and 2.8 (95% CI, 2.3–3.5), respec- tively.6 In a large Rotterdam (Netherlands), population- information is hard to based prospective study of people aged 55 years or above, it hide was estimated that 17% of the overall risk of AD could be attributed to the e4 allele, with 3% (95% CI, 0–6%) of cases attributed to the e4/e4 genotype, and 14% (95% CI, 7–21%) European Journal of Human Genetics (2009) 17, 147–149; 7 to the e4/e3 genotype. doi:10.1038/ejhg.2008.198; published online 22 October 2008 A recent investigation of LD for 50 SNPs in and surrounding APOE in 550 Caucasians identified multiple SNPs in the TOMM40 gene B15 kb upstream of APOE, and The recent publication and release to public databases of at least one SNP in the other surrounding genes LU, PVRL2, Dr James Watson’s sequenced genome,1 with the exception APOC1, APOC4 and CLPTM1 were associated with LOAD of all gene information about apolipoprotein E (ApoE), risk.8 In particular, the C allele of SNP rs157581 in provides a pertinent example of the challenges concerning TOMM40 is in strong LD (r240.6) with the C allele of privacy and the complexities of informed consent in the rs429358 in APOE, which defines the e4 allele. -
Synthetic Biology - Mapping the Patent Landscape Paul Oldham 1,2 Stephen Hall 3 1
bioRxiv preprint doi: https://doi.org/10.1101/483826; this version posted November 30, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Synthetic Biology - Mapping the Patent Landscape Paul Oldham 1,2 Stephen Hall 3 1. Industrial Fellow, Manchester Institute of Innovation Research, Alliance Manchester Business School, Manchester University. 2 Senior Visiting Fellow, Institute for the Advanced Study of Sustainability, United Nations University 3. Information System Services, Lancaster University Abstract This article presents the global patent landscape for synthetic biology as a new and emerging area of science and technology. The aim of the article is to provide an overview of the emergence of synthetic biology in the patent system and to contribute to future research by providing a high quality tagged core dataset with 7,424 first filings and 71,887 family members. This dataset is intended to assist with evidence based exploration of synthetic biology in the patent system and with advancing methods for the analysis of new and emerging areas of science and technology. The starting point for the research is recognition that traditional methods of patent landscape analysis based on key word searches face limitations when addressing new and emerging areas of science and technology. Synthetic biology can be broadly described as involving the design, synthesis and assembly of biological parts, circuits, pathways, cells and genomes. As such synthetic biology can be understood as emerging from a combination of overlaps and convergences between existing fields and disciplines, such as biotechnology, genetic engineering, protein engineering and systems biology. -
Scientists Create Cell Based on Man-Made Genetic Instructions
25-5-2010 Scientists create cell based on man-m… Scientists create cell based on man•made genetic instructions By David Brown Friday, M ay 21, 2010; A03 Scientists reported Thursday that they have created a cell controlled entirely by man•made genetic instructions •• the latest step toward creating life from scratch. The achievement is a landmark in the emerging field of "synthetic biology," which aims to control the behavior of organisms by manipulating their genes. Although the ultimate goal of creating artificial organisms is still far off, the experiment points to a future in which microbes could be manufactured with novel functions, such as the ability to digest pollutants or produce fuels. Some ethicists fear that the strategy could also be used to produce biological weapons and other dangerous life forms. In a paper published online by the journal Science, researchers from the J. Craig Venter Institute described using off•the•shelf chemicals and the DNA sequence of Mycoplasma mycoides's genes to make an artificial copy of the bacterium's genome. The scientists then transplanted that genome into the cell of a different (but closely related) microbe. The donor genome reprogrammed the recipient cell, which went on to replicate and divide. The result was new colonies of Mycoplasma mycoides. "We think these are the first synthetic cells that are self• replicating and whose genetic heritage started in the computer. That changes conceptually how I think about life," said J. Craig Venter, 63, who gained fame a decade ago as the co•sequencer of the human genome. His institute has laboratories and offices in Rockville and San Diego. -
Biographical Memoirs
National Academy of Sciences - Biographical Memoirs http://www.nasonline.org/publications/biographical-memoirs/online-collection.html By Michael P. Filosa Flack Norris (1871-1940) for the November Nucleus, I came across his biographical memoir on the website of the National Academy of Sciences (NAS). This memoir was written by John D. Roberts and was presented to the Academy in 1974, a scant(!) 34 years after his death. The NAS was founded in 1863 by 50 of the most prominent scientists in the United States, and its initial charter was signed by Abraham Lincoln. It is a tradition that each of its members be memorialized in a memoir to the Academy written by a peer (or two). These memoirs are a treasure trove of the history of science. The sole weakness is that they are posthumous and not necessarily, very timely. However, they are quite thorough and a good overview of the scientists, complete with a detailed listing of their major works. During my school years, I was always intrigued with stories about great scientists. Dan Kemp would talk extensively about his thesis advisor, R. B. Woodward, and his works. Those stories about Woodward (1917-1979) and also Gilbert Stork were very influential in my decision to pursue synthetic organic chemistry as a career. Woodward’s memoir was written by Elkan Blout (with assistance from Frank Westheimer) and was published in 2001, a “scant” 22 years after his death. The memoirs are often glowing: “Robert Burns Woodward was the preeminent organic chemist of the twentieth century. This opinion is shared by his colleagues, students and by other distinguished chemists.” Blout includes lengthy commentaries from Sir Derek Barton, Roald Hoffman and Albert Eschenmoser in the memoir.